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ABSTRACT: Comprehensive analyses of results from
genome-wide association studies (GWAS) have demon-
strated that complex disease/trait-associated loci are en-
riched in gene regulatory regions of the genome. The
search for causal regulatory variation has focused primar-
ily on transcriptional elements, such as promoters and
enhancers. microRNAs (miRNAs) are now widely ap-
preciated as critical posttranscriptional regulators of gene
expression and are thought to impart stability to biologi-
cal systems. Naturally occurring genetic variation in the
miRNA regulome is likely an important contributor to
phenotypic variation in the human population. However,
the extent to which polymorphic miRNA-mediated gene
regulation underlies GWAS signals remains unclear. In
this study, we have developed the most comprehensive
bioinformatic analysis pipeline to date for cataloging and
prioritizing variants in the miRNA regulome as functional
candidates in GWAS. We highlight specific findings, in-
cluding a variant in the promoter of the miRNA let-7 that
may contribute to human height variation. We also pro-
vide a discussion of how our approach can be expanded in
the future. Overall, we believe that the results of this study
will be valuable for researchers interested in determining
whether GWAS signals implicate the miRNA regulome
in their disease/trait of interest.
Hum Mutat 34:1049–1056, 2013. C© 2013 Wiley Periodicals, Inc.
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Introduction
In the past 6 years, genome-wide association studies (GWAS) have
identified over 7,000 unique genetic loci associated with hundreds
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of complex traits and diseases [Hindorff et al., 2009]. Comprehen-
sive analyses of these findings have found that GWAS signals are
significantly overrepresented in regulatory regions of the genome
[Ernst et al., 2011; Hindorff et al., 2009; Maurano et al., 2012; Nica
et al., 2010; Nicolae et al., 2010; Schaub et al., 2012]. Moreover, sev-
eral follow-up functional studies have identified specific regulatory
elements that underlie genetic associations and are directly impli-
cated in complex disease etiology [Gaulton et al., 2010; Harismendy
et al., 2011; Musunuru et al., 2010; Pomerantz et al., 2009; Stitzel
et al., 2010]. Although much of the focus on regulatory variation
has been centered on transcriptional elements, such as promoters
and long-range enhancers [Degner et al., 2012], a seminal study
from the Georges lab in 2006 found the first example of a variant
in a microRNA (miRNA) target site contributing to a disease phe-
notype (muscular hypertrophy in Texel sheep) [Clop et al., 2006].
Five years later, Brest et al. (2011) identified the very first case of a
human GWAS signal that may be explained by polymorphic miRNA
targeting—a synonymous variant that alters a miR-196 target site
and influences risk for Crohn’s disease [Georges 2011]. Follow-
ing that report, another group implicated the miR-137 locus in
schizophrenia (2011), though the molecular mechanism underlying
the association remains unclear. Most recently, in 2012, Richardson
et al. (2012) demonstrated that a variant in the 3′-untranslated re-
gion (3′-UTR) of lipoprotein lipase (LPL) disrupts the binding of
miR-410 and modulates the effect of diet on plasma lipid levels.
These findings highlight the importance of expanding the view of
the regulatory variation landscape beyond chromatin and transcrip-
tional control elements.
miRNAs are short (∼22 nucleotide) noncoding RNAs that
regulate gene expression principally at the posttranscriptional
level [Bartel 2009]. The human genome encodes for over 1,000
miRNAs in either intragenic regions or independent transcription
units [Griffiths-Jones et al., 2008; Kozomara and Griffiths-Jones
2011]. miRNA loci are transcribed predominantly by RNA Poly-
merase II [Cai et al., 2004; Lee et al., 2004], yielding primary tran-
scripts (pri-miRNAs) of highly variable length depending on the
locus [Saini et al., 2008; Stitzel et al., 2010]. The pri-miRNA is
processed within the nucleus by the ribonuclease Drosha and its co-
factors, generating one or more precursor sequences (pre-miRNAs)
with a hairpin-like secondary structure [Kim 2005; Kim et al., 2009].
The pre-miRNA is then exported to the cytoplasm, where it is subject
to further enzymatic processing by Dicer and its partners, producing
a∼22 bp double stranded RNA duplex. One strand of this duplex, re-
ferred to as the mature miRNA, is loaded onto the RNA-induced si-
lencing complex (RISC). The miRNA guides and tethers the RISC to
C© 2013 WILEY PERIODICALS, INC.
specific target RNAs to regulate their stability and/or translation
[Bartel 2009].
The miRNA regulome (defined as the compendium of regula-
tory elements that either regulate miRNA expression or are regu-
lated by miRNA activity) is a critical component of the biological
networks that govern cellular and systemic phenotypes [Gennar-
ino et al., 2012; Liang and Landweber 2007; Volinia et al., 2010].
miRNAs have emerged as stable plasma biomarkers for disease di-
agnosis and prognosis [Mitchell et al., 2008], and as promising
therapeutic targets for a growing number of disorders [Jackson and
Levin 2012; van Rooij et al., 2012]. Recent studies of genetic variation
in human populations demonstrated that purifying selection has
constrained the genetic diversity of the miRNA Regulome [Chen
and Rajewsky 2006; Hu and Bruno 2011; Li et al., 2012a; Quach
et al., 2009; Saunders et al., 2007]. In fact, Chen and Rajewsky re-
ported in their seminal 2006 study that negative selection may be
stronger on predicted conserved miRNA target sites than on most
other functional classes of genomic elements, including nonsyn-
onymous sites [Chen and Rajewsky 2006]. These findings suggest
that genetic variation in the miRNA regulome may have strongly
deleterious phenotypic consequences. Notably, however, several of
the same studies also identified islands of the miRNA regulome
that have been subject to recent positive selection [Li et al., 2012a;
Liang and Li 2009; Quach et al., 2009; Saunders et al., 2007]. Taken
together, these observations indicate that genetic variation in the
miRNA regulome contributes to both population adaptation and
complex disease etiology.
Human genetic variation in the miRNA regulome, particularly
miRNA target sites, has been extensively catalogued [Barenboim
et al., 2010; Bhattacharya et al., 2012; Gong et al., 2012; Hariharan
et al., 2009; Hiard et al., 2010; Landi et al., 2011; Schmeier et al., 2011;
Zorc et al., 2012], and has been demonstrated to have widespread
effects on miRNA-mediated gene regulation [Gamazon et al., 2012;
Kim and Bartel 2009; Lu and Clark 2012]. Although the extent to
which polymorphic miRNA-mediated gene regulation contributes
to phenotypic variation is not clear [Sethupathy and Collins 2008],
it is an area that could have broad implications for disease biology
[Borel and Antonarakis 2008; Chen et al., 2008; Gamazon et al.,
2012; Georges et al., 2007] and pharmacogenomics [Mishra et al.,
2008] and as such, clearly merits further investigation.
Over the last 2 years, several bioinformatic strategies and web
servers have been developed to facilitate the identification of vali-
dated GWAS signals that alter the miRNA regulome [Arnold et al.,
2012; Bruno et al., 2012; Li et al., 2012b; Richardson et al., 2011;
Thomas et al., 2011; Ziebarth et al., 2012]. However, these ap-
proaches harbor several major limitations that hinder the effective
prioritization of variants for functional validation. In this study, we
present the most comprehensive strategy to date that addresses each
of these limitations. We highlight specific findings and also discuss
how the approach can be expanded in the future. We believe that the
results of this study will be very valuable for researchers interested in
determining whether GWAS signals implicate the miRNA regulome
in their disease/trait of interest.
Materials and Methods
Defining Linkage Disequilibrium Blocks of Trait/Disease
Association
The NHGRI GWAS catalog (as of 11/14/12) was mined for all
single nucleotide polymorphisms (SNPs) reported to be associated
(P < 1.0 × 10–5) with a trait/disease. For simplicity sake, multi-SNP
haplotypes (n = 46) were not considered. For each study, the follow-
ing information was recorded: first author, row number in GWAS
catalog, PubMed ID, index SNP ID, trait/disease, case–control co-
hort ancestry, and association P value.
Each GWAS was assigned to one of four super-populations in the
1000 Genomes Project (1000G) according to the mapping scheme
described in Box 1. For each index SNP reported in each GWAS,
1000G SNPs in linkage disequilibrium (LD) (defined as r2 > 0.6) were
identified by mining the 1000G phase I haplotype data for the as-
signed super-population (http://www.sph.umich.edu/csg/yli/mach/
download/1000G.2012-02-14.html). For every SNP in an LD block
of association, the following information from 1000G was recorded:
chromosomal location (hg19), extent of LD with index SNP (r2), and
minor allele identity/frequency in the assigned super-population.
BOX 1. GWAS Assignments to One of Four
Super-Populations of the 1000 Genomes
Project


























Anything else EUR (European)
miRNA Regulome Datasets
Human miRNA and pre-miRNA locations were downloaded
from miRBase version 18 (http://www.mirbase.org/). Promoter re-
gions of human miRNAs were obtained from epigenomic studies
in two primary human cell types: CD4+ T cells [Barski et al., 2009]
and pancreatic islets [Stitzel et al., 2010]. 3′-UTR sequences from
the reference genomes of human, mouse, rat, dog, and chicken were
downloaded from TargetScan 6.1 (http://www.targetscan.org/cgi-
bin/targetscan/data_download.cgi?db=vert_61). Coordinates for
the human 3′-UTR sequences were obtained by running a command
line version of BLAT against the human genome (hg19). 3′-UTRs
that mapped perfectly to multiple locations, or that appeared to be
spliced, or were of length <20 nt (BLAT requires sequences >20 nt)
were discarded from the analysis. For each 3′-UTR, the RefSeq
ID provided by TargetScan 6.1 was converted to the official gene
symbol using the BioMart database (http://useast.ensembl.org/
biomart/martview/).
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Human miRNA target sites were predicted within the reference
3′-UTR sequences using the TargetScanS algorithm (written in Perl
and executed on a local server). For each prediction, the follow-
ing information was recorded: miRNA name, gene symbol, target
site type (7mer-1a, 7mer-m8, and 8mer-1a, in order of increasing
efficacy), and a conservation number (1–5, indicating the number
of species among [human, mouse, rat, dog, chicken] in which the
putative target site is exactly conserved; a value of 1 indicates that
the site is present only in the human and not in any of the other four
species analyzed).
For each human 3′-UTR reference sequence, the allelic comple-
ment was generated by replacing every reference allele with the
nonreference allele at each bi-allelic polymorphic locus reported by
1000G. If two or more SNPs are within the span of a target site (7 nt),
all combinations of reference and alternate alleles at these sites were
considered (e.g., if two A/T SNPs are within 7 nt, each of the poten-
tial AT, TA, and TT haplotypes would be considered). Many SNPs in
close proximity are likely to be in strong LD; therefore, some of these
allelic combinations are likely very rare. However, they have been
included for comprehensiveness. Human miRNA target sites were
predicted within the allelic complement 3′-UTR sequences using the
TargetScanS algorithm. For each prediction, the same information
as for predictions in the reference 3′-UTRs was recorded.
Other Functional Annotation Datasets
 Coding exons were downloaded from the “knownGenes”
table on the UCSC Table Browser (https://genome.ucsc.edu/
cgi-bin/hgTables).
 Nonsynonymous SNPs (nonsense, missense, frameshift) were
downloaded from dbSNP build 137 (ftp://ftp.ncbi.nih.gov/snp/
organisms/human_9606/VCF/00-All.vcf.gz).
 Transcriptional SNPs were downloaded from RegulomeDB
(http://regulome.stanford.edu/downloads).
 Expression quantitative trait loci (eQTLs) in lymphocytes were
obtained from (P.F. Sullivan, unpublished data).
 Validated miRNA:target-gene pairs were downloaded from
TarBase 5.0 (http://diana.cslab.ece.ntua.gr/tarbase/tarbase_
download.php).
Identification of Candidate miRNA Regulatory Hubs
Candidate gene lists for each trait/disease were extracted from
the NHGRI GWAS catalog. For each trait/disease, potential miRNA
regulatory hubs in the underlying gene network were identified by
Monte Carlo simulation analysis. First, the seed-based TargetScanS
algorithm was used to determine the number of predicted conserved
targets in the gene list for each miRNA. This number was converted
to a score by weighting 8-mer seed matches or target sites within
60 nt by a factor of 1.5. This procedure was repeated 100,000 times
with a new set of randomly selected genes from the human genome
each time, to generate a background expectation of the targeting
score for each miRNA, which was then used to calculate an empirical
P value for the score obtained with the candidate gene list for the
trait/disease. To account for differences in the average 3′-UTR length
between the trait/disease genes of interest and the randomly selected
genes in each simulation, the number of predicted target genes was
normalized to the average 3′-UTR length in the following manner.






Tn is the normalized number of predicted target genes in a random
simulation, T is the actual number of predicted target genes in a
random simulation, L (t) is the average length of the 3′-UTRs in the




We developed an integrative genomic pipeline to catalog and
prioritize trait/disease-associated single nucleotide polymorphisms
(TASs) in the miRNA regulome. TASs include SNPs reported by
GWAS (index SNPs) and all other SNPs in strong LD. We describe
below five features of our strategy that represent conceptual and/or
empirical advances relative to the existing approaches:
(1) Inclusion of nonconserved miRNA target sites. Current ap-
proaches have largely restricted their analyses to predicted
miRNA target sites that are highly conserved. However, recent
integrative genomic analyses indicate that GWAS loci are en-
riched in nonconserved regions of the genome [Gaffney et al.,
2012; Schaub et al., 2012]. Therefore, it is likely that overlook-
ing lineage-specific miRNA target sites misses many causative
variants. We have included in our pipeline any miRNA target
site that is predicted in the human genome regardless of the
extent of cross-species conservation (Methods).
(2) Definition of LD blocks of association using data from the 1000
Genomes Project. Current approaches compute LD using geno-
type data from the International HapMap project [Altshuler
et al., 2010]. Instead, we have chosen to define LD blocks based
on the sequence data from phase I of the 1000 Genomes Project
(1000G) (Methods), because it provides the highest resolution
human genetic map to date [Abecasis et al., 2012]. Specifi-
cally, compared with HapMap, the 1000G resource doubles the
number of variants that are in LD with each GWAS index SNP
[Abecasis et al., 2012].
(3) Definition of population-specific LD blocks of association. Cur-
rent approaches consider only the LD structure in HapMap
individuals of European descent. To account for the increas-
ing number of GWAS in non-European populations and the
varying LD patterns across different populations, we have de-
fined LD blocks for each index SNP from each GWAS using the
1000G data for the “super population” (African, Asian, Amer-
ican, European) that most closely matches the ancestry of the
case-control cohort used in the GWAS (Methods).
(4) Inclusion of miRNA promoter regions. Until recently, promoters
of miRNAs were largely unknown and were not considered in
most surveys of genetic variation in the miRNA regulome. In
last few years, several groups, including our own, have used
large-scale epigenomic strategies to annotate comprehensively
the promoter regions of miRNAs [Barski et al., 2009; Corcoran
et al., 2009; Marson et al., 2008; Ozsolak et al., 2008; Stitzel et al.,
2010]. Given that genetic variants in miRNA promoters could
alter miRNA expression and function [Luo et al., 2011], and
that gene promoters are enriched for GWAS loci [Hindorff et al.,
2009], we have incorporated miRNA promoter annotations
from two different studies into the analysis pipeline (Methods).
(5) Functional annotation of all SNPs within LD association blocks to
assess the likelihood that the association signal is explained by the
miRNA regulome. Current approaches do not assess whether the
association signal is likely to be explained by a gene regulatory
mechanism, and if it is, whether any of the genetic variants in
the associated LD block may have other (non-miRNA-related)
compelling regulatory annotations. Therefore, for every TAS in
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the miRNA regulome, we annotate whether any of the SNPs
in the corresponding GWAS LD block occur at exons, nonsyn-
onymous sites, and/or transcriptional regulatory elements as
defined by RegulomeDB [Boyle et al., 2012], which includes all
of the high-throughput experimental datasets generated by the
Encyclopedia of DNA Elements (ENCODE) Project[Dunham
et al., 2012]. TASs in LD blocks uniquely associated with the
miRNA regulome (i.e., LD blocks that do not harbor any other
exonic or transcriptional SNP) are deemed to be of highest
priority for functional validation. Finally, for every candidate
miRNA:trait pair that we identify, we perform a Monte Carlo
simulation to determine whether the miRNA is a candidate
regulatory hub in the network of genes implicated in the trait
by GWAS.
Trait/Disease-Associated Genetic Variants in
the miRNA Regulome
Our integrative analysis of the NHGRI GWAS catalog and the
1000G database identified 211,687 unique TASs (Fig. 1). Of these,
12, 41, and 2,041 TASs occur within miRNA precursors, miRNA
promoter regions, and 3′-UTRs, respectively.
miRNA precursors
The low density of TASs in pre-miRNAs is consistent with previ-
ous reports and is suggestive of negative selection on miRNA loci.
Of the 12 TASs within pre-miRNAs, six are in GWAS LD blocks
that do not contain any known exonic variant (Fig. 1). Among these
six is rs12803915 (Table 1; Supp. Table S1), which is located within
the precursor of a primate-specific miRNA (miR-612), and is in
moderate LD (1000G EUR, r2 = 0.6) with a reported index SNP
(rs17146964) for vertical cup-disc ratio (CDR; a parameter linked
to glaucoma risk) in a case-control cohort of European ancestry.
A very recent study demonstrated in several cell lines that the mi-
nor allele of rs12803915 significantly alters the cellular processing
of pre-miR-612 and, consequently, the expression levels of mature
Table 1. Selected Examples of Trait/Disease-Associated SNPs











rs12803915 21.4% (EUR) miR-612 Pre-miRNA
Pulse rate rs6701558 11.2% (ASN) miR-29b/c Promoter region
Schizophrenia rs2660302 21.8% (EUR) miR-137 Promoter region
Height rs113431232 3.4% (EUR) let-7a/d/f Promoter region
Pigmentation rs35407 2.2% (EUR) miR-27 SLC45A2 target site
Body mass index rs77632545 19.9% (ASN) miR-181a ZNF169 target site
Asthma rs17052784 2.6% (EUR) miR-140-3p DCLK1 target site
Plasma C-reactive
protein levels
rs116971887 4.9% (EUR) miR-194 SALL1 target site
Type 1 diabetes
autoantibodies
rs3842753 50.0% (EUR) miR-491-5p INS target site
Type 2 diabetes rs1802295 50.0% (ASN) miR-510 VPS26A target site
Of the 42 TASs that are in the miRNA regulome and are not in LD with annotated
nonsynonymous or transcriptional SNPs, 10 are shown here (pre-miRNA, n = 1; miRNA
promoter, n = 3; miRNA target site, n = 6). Minor allele frequencies (MAFs) are specific
to the 1000G super-population (ASN, Asian; EUR, European; AMR, American; AFR,
African) that is closest to the ancestry of the case-control cohort in the GWAS that
identified the genetic association. MAFs of the miRNA regulome SNPs range from
relatively rare (e.g., rs35407, EUR MAF = 0.022) to very common (e.g., rs1802295, ASN
MAF = 0.5).
miR-612 [Kim et al., 2012]. This pre-miRNA TAS is a compelling
candidate for further validation as a determinant of CDR.
miRNA promoter regions
Of the 41 TASs within miRNA promoters, 16 are in GWAS LD
blocks that do not contain any known exonic variant (Fig. 1). Among
these 16 is rs6701558 (Table 1; Supp. Table S1), which is within the
promoter of the miR-29b-2/miR-29c cluster, and is in complete LD
(1000G ASN, r2 = 1) with a reported index SNP (rs12731740) for
pulse rate in a cohort of Asian ancestry. This finding is consistent
with the recent observation that the miR-29 family of miRNAs con-
trol aortic dilation and aneurysm formation [Boon et al., 2011],
which directly influence heart rate. Another compelling candidate
for functional evaluation is rs2660302 (Table 1; Supp. Table S1),
which occurs within the promoter of miR-137, and is in LD (1000G
EUR, r2 = 0.71) with an index SNP (rs1625579) for schizophrenia in
a cohort of European ancestry. Two previous studies demonstrated
that miR-137 is a candidate regulatory hub in the schizophrenia gene
network [2011; Potkin et al., 2010]. The rs2660302 locus may medi-
ate allele-dependent transcriptional regulation of miR-137, thereby
altering the expression status of genes underlying the etiology of
schizophrenia.
To identify the most compelling functional candidates among
the remaining 15 miRNA promoter TASs, we implemented a
Monte Carlo simulation strategy to determine for each of the
15 miRNA:trait pairs whether the miRNA is predicted to target sig-
nificantly more of the protein-coding genes implicated in the trait
by GWAS than expected by chance. The most striking result was
for the pair let-7:height (Fig. 2A). Specifically, we found that pre-
dicted target sites for let-7 are the most significantly overrepresented
within the 3′-UTRs of genes at loci associated with human stature
(Fig. 2A). The TAS (rs113431232) located within the let-7 promoter
region has a minor allele frequency (MAF) of ∼3% in the 1000G
population of European ancestry and is in LD (1000G EUR, r2 = 0.74)
with a reported index SNP (rs1257763) for height (Table 1; Supp.
Table S1). We mined the ENCODE database and determined that
this TAS occurs within a region of open chromatin in many cell
types (Fig. 2B), highlighting the possibility that it may influence
the transcriptional activity of the locus. We then analyzed the EN-
CODE data generated by chromatin immunoprecipitation followed
by high-throughput sequencing (ChIP-seq) and found that the TAS
overlaps a high-confidence binding site in HeLa cells for the tran-
scription factor E2F4 (Fig. 2B). Notably, a recent study validated
this binding site by ChIP-PCR and also demonstrated that overex-
pression of E2F4 in HeLa cells leads to down-regulation of let-7 [Lee
et al., 2011]. This finding is consistent with the known oncogenic
and tumor suppressive capacity of E2F4 and let-7, respectively [Bei-
jersbergen et al., 1994; Roush and Slack 2008]. The minor allele at
rs113431232 may disrupt E2F4 binding, thereby upregulating let-7
and altering the expression of targets that influence cell growth and,
ultimately, human stature.
miRNA target sites
Of the 2,041 TASs located in 3′-UTRs, 1,763 create and/or abolish
predicted target sites for human miRNAs (Fig. 1; Supp. Table S2).
One of these, rs13702, has recently been validated by rigorous follow-
up genetic and molecular studies [Richardson et al., 2012]. Specifi-
cally, Richardson et al. (2012) demonstrated that the rs13702 minor
allele reduces plasma lipid levels by abolishing a miR-410 target site
in the 3′-UTR of LPL, which leads to increased LPL expression and
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Figure 1. Summary of the analysis pipeline. The primary data sources (pink rectangles) and the number of trait-associated SNPs (blue rectangles)
passing each filter (red text) in the analysis pipeline are shown. ∗, candidate miRNA regulatory hubs are identified for each trait/disease using a
Monte Carlo simulation strategy (Methods).
Figure 2. A genetic variant in the let-7 promoter may contribute to human height variation. A: Each data point represents a human miRNA and
the y-axis shows the log10 of the P value of miRNA target site enrichment among genes implicated in height by GWAS. The dashed line denotes the
significance threshold (empirical P = 0.01). B: SNP rs113431232, which is in LD with an index SNP (rs1257763) for height, occurs in a validated E2F4
binding site within the promoter region of the let-7a/d/f miRNA cluster. H3K4me3 (histone H3 lysine 4 tri-methylation) ChIP-seq signal (ENCODE)
denotes promoter regions; DNase HS (DNase I hypersensitive site) signal (ENCODE) denotes open chromatin; E2F4 ChIP-seq signal (ENCODE)
denotes chromatin occupancy of transcription factor E2F4. Peak E2F4 occupancy signal (red rectangle) occurs within a local dip in the DNase HS
signal, which is indicative of a bound transcription factor(s). All ENCODE data shown are from HeLa cells.
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activity. Two other TASs, rs12537 and rs12904, which are associated
with IgA nephropathy and gamma-glutamyl transferase (GGT) lev-
els, respectively, have been implicated previously in gastric cancer by
candidate gene association studies. In vitro molecular experiments
have confirmed that the rs12537 minor allele creates a miR-181a
target site in MTMR3 [Lin et al., 2012] and that the rs12904 minor
allele disrupts a highly conserved miR-200bc target site in EFNA1
[Li et al., 2012c]. However, neither has yet been verified as the mech-
anistic link for the genetic association with IgA nephropathy and
GGT levels, respectively. Although both rs12537 and rs12904 are
in strong LD with nonsynonymous variants and SNPs in predicted
transcriptional regulatory elements (Supp. Table S2), the miRNA-
related mechanism may merit further investigation. We performed
an analysis of TarBase 5.0, a repository of experimentally supported
miRNA:target-gene pairs (Methods), and identified one additional
TAS (rs891368) that occurs within a predicted miRNA target site for
a gene (RFT1) that has been previously demonstrated to be regulated
by the same miRNA (miR-15). rs891368 is in perfect LD (r2 = 1)
with a reported index SNP (rs2336725) for height (Supp. Table S2).
Among the 1,763 TASs within miRNA target sites, 42 are in GWAS
LD blocks that do not contain either a nonsynonymous or a tran-
scriptional regulatory variant (Fig. 1; Supp. Table S2). Of these, 26
are either in very strong LD (r2 > 0.9) with the reported index SNPs
or are the index SNPs themselves. Several such TASs are highlighted
in Table 1, two of which are described in further detail below.
The minor allele at rs116971887 disrupts a highly conserved pre-
dicted miR-194 target site within the gene SALL1, and is in strong
LD (1000G EUR, r2 = 0.92) with a reported index SNP for plasma
C-reactive protein (CRP) levels (Table 1; Supp. Table S2), which is
a strong indicator of cardio-metabolic status [Onat et al., 2008].
SALL1 is critical for normal development and function of the kid-
ney [Abedin et al., 2011; Nishinakamura and Takasato 2005], where
miR-194 expression is highly enriched [Senanayake et al., 2012].
CRP is produced in the kidney in response to inflammatory signals
[Jabs et al., 2003] and is associated with abnormalities in kidney
function [Stuveling et al., 2003]. The minor allele at rs116971887
is predicted to abrogate the miR-194 target site, thereby potentially
increasing SALL1 expression levels. The question of whether this
would lead to increased plasma CRP merits further detailed exper-
imentation.
The minor allele at rs77632545 is predicted to create a new target
site for miR-181a within the 3′-UTR of ZNF169, and is in strong LD
(1000G ASN, r2 = 0.95) with a reported index SNP for body mass
index (BMI). ZNF169 is a member of the zinc-finger family of genes,
which have been identified as harboring unusually effective coding
region target sites specifically for miR-181a [Huang et al., 2010;
Schnall-Levin et al., 2011]. It has also been demonstrated that when
miRNAs bind to messenger RNAs in both the coding region and
the 3′-UTR the repressive effect on protein expression is synergistic
[Fang and Rajewsky 2011]. Therefore, by creating a new miR-181a
target site, the minor allele at rs77632545 could induce significantly
decreased levels of ZNF169. Further investigation is required to
determine whether altered expression of ZNF169 is associated with,
or can directly influence, BMI and related phenotypes.
Discussion
We have developed the most comprehensive approach to date for
cataloging trait/disease-associated genetic variation in the miRNA
regulome. Our analysis pipeline provides a concrete means of pri-
oritizing variants in the miRNA regulome as functional candidates
in GWAS. We described here specific miRNA-related variants that
may explain genetic associations with a variety of traits/diseases,
including body mass index, IgA nephropathy, and schizophrenia.
Our study is the first to catalog systematically trait/disease-
associated genetic variants in miRNA promoter regions. These pro-
moters were obtained from epigenomic analyses conducted in two
different human cell types [Barski et al., 2009; Stitzel et al., 2010]. In
future genetic analyses of the miRNA regulome, it will be meaningful
to include a more comprehensive set of miRNA promoters, which
can be identified by analyzing relevant chromatin data that have
been generated by the ENCODE and NIH Epigenomics Roadmap
consortiums for a wide array of different cell types and physiologic
conditions. Furthermore, the application of chromosome confor-
mation capture technology may facilitate the identification of long-
range regulatory elements (e.g., enhancers and silencers) that con-
tribute to the control of miRNA expression, and may also harbor
trait/disease-causing genetic variants.
In our survey, we included the broadest set to date of predicted
miRNA target sites based on an algorithm that identifies sequences
within 3′-UTRs that are exactly complementary to the 5′-end of a
miRNA, referred to as the “seed” region [Friedman et al., 2009]. It
has been demonstrated that some miRNAs have alternative modes of
target recognition that do not require a seed match [Brennecke et al.,
2005; Chi, et al., 2012; Shin et al., 2010]. Also, miRNAs can effectively
target regions outside the 3′-UTR, including the open reading frame
[Forman and Coller 2010]. Incorporating these categories of target
sites will expand the functional miRNA regulome and facilitate the
identification of trait/disease associated genetic variants that disrupt
miRNA activity.
It is worth noting that variants beyond the miRNA regulome can
still affect miRNA activity. For example, it has been demonstrated
that 3′-UTR variants outside of a miRNA target site can influence
miRNA targeting efficacy [Mishra et al., 2007], potentially by alter-
ing local secondary structure and accessibility to the miRNA-RISC
[Haas et al., 2012]. It is well established that genetic variants can
alter mRNA folding [Shen et al., 1999], which in turn can influence
function [Halvorsen et al., 2010]. Very recently, high-throughput
approaches have been developed to resolve RNA structures [Deigan
et al., 2009; Lucks et al., 2011] toward the goal of predicting the effect
of specific variants on secondary and tertiary RNA conformation
[Ritz et al., 2012]. As these strategies become increasingly tractable,
it will be of great interest to assess the extent to which trait/disease-
associated genetic variants that are not explicitly within the miRNA
regulome nevertheless disrupt miRNA activity.
In summary, our strategy improves upon the accuracy and reso-
lution of previous approaches and, importantly, facilitates the pri-
oritization of genetic variants in the miRNA regulome as functional
candidates in GWAS. Although we do not provide experimental
validation in this study, we have highlighted specific examples that
merit further detailed investigation, including a SNP associated with
height that occurs within a validated E2F4 binding site in the let-7
promoter, and a SNP associated with vertical CDR that has been
shown to alter miR-612 biogenesis. The bioinformatic pipeline pre-
sented in this study can be extended in the future to incorporate
many other types of genomic data, such as miRNA expression pat-
terns and somatic mutations in cancer.
Complex diseases are increasingly viewed as “network disorders”
[Sullivan 2012]. Biological networks often have mechanisms for
conferring robustness against genetic and/or environmental pertur-
bation, in part due to a web of miRNA activity [Ebert and Sharp
2012]. Therefore, genetic variants that alter miRNA activity will
likely have a dramatic effect on network output. We expect that as
more high-powered genetic association studies are performed, and
as the functional miRNA regulome is brought into clearer view, an
1054 HUMAN MUTATION, Vol. 34, No. 8, 1049–1056, 2013
increasing number of miRNA-related variants will be implicated in
complex disease etiology.
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